UCB May Be Stagnating Today, But Promises There Will Be Growth Tomorrow
This article was originally published in The Pink Sheet Daily
Generics hit UCB's 2009 sales hard, but the mid-cap pharma is looking to new drugs Cimzia and Vimpat for a return to growth.
You may also be interested in...
For about $670 million, GSK acquires UCB drugs and infrastructure in several dozen non-BRIC markets.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.